Located in La Rochelle, on the premises of a long-standing Spineway partner, the new line includes a clean room for injection operations. In line with the schedule 1, the first LP-ESP prostheses went ...

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and ...

Vesting of each stock option is subject to such employee's continued service to Taysha on each vesting date. About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage ...

Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the ...

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq.

IRB approval from TASMC follows Clearmind’s prior regulatory milestones, including U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application and IRB approvals ...

AI Code of Conduct’s six core principles key to ensuring the safe and effective use of AI technologies ...

The Foundation has been awarded the Gold Seal for Transparency by Guidestar for eight consecutive years. Your contributions support its mission to defend taxpayers and cancer patients by advocating ...

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are ...

On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to employees and board ...